# Biomea Fusion Reports Phase 1 Results for BMF-650 Showing Up to 6.1% Weight Loss

- URL: https://stocks.freetheai.org/news/biomea-fusion-reports-phase-1-results-for-bmf-650-showing-up-to-6-1-weight-loss-8f2d93
- Published: 2026-10-14T10:03:00Z
- Category: company_news; sentiment: mixed; impact: medium
- Symbols: [NASDAQ:BMEA](https://stocks.freetheai.org/symbols/NASDAQ-BMEA)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Biomea Fusion, Inc. (BMEA) announced positive Phase 1 topline clinical data for BMF-650, its experimental weight-loss drug candidate. Across initial dosing groups, patients demonstrated dose-dependent weight reduction ranging from 1.5% to 3.2% at Day 29, compared to 0.1% for placebo. A high-dose group following a rapid escalation schedule achieved a mean weight loss of 6.1% over the same 29-day period.

The trial results showed favorable safety and tolerability. All treatment-emergent adverse events across five multiple ascending dose cohorts were mild or moderate, with no severe adverse events, dose reductions, or patient dropouts reported. Gastrointestinal side effects at the highest dose level remained low, with nausea and vomiting each affecting 12.5% of participants in that cohort. Furthermore, pharmacokinetic data indicated steady drug exposure, supporting the possibility of a once-daily dosing routine without mandatory dose titration.

Despite the clinical findings, shares of Biomea Fusion Inc fell 7.35% to 1.26 USD. Investors will be monitoring future development steps for BMF-650, including potential larger Phase 2 trials to evaluate longer-term efficacy, dosing schedules, and competitive positioning against rival oral obesity treatments.

## Key points

- Biomea Fusion reported Day 29 mean weight loss ranging from 1.5% to 3.2% across lower dose cohorts compared to 0.1% in the placebo group.
- The highest-dose cohort achieved a 6.1% average weight reduction at Day 29 under a rapid dose escalation schedule.
- No severe or serious adverse events, dose modifications, or patient discontinuations were reported across all five trial cohorts.
- Pharmacokinetic data showed sustained exposure supporting once-daily dosing with a potential no-titration 400 mg regimen.

## Questions and answers

### What were the main weight loss results from Biomea Fusion's Phase 1 trial?

Patients in lower-dose cohorts achieved between 1.5% and 3.2% mean weight loss at Day 29 compared to 0.1% for placebo. The highest-dose cohort recorded a 6.1% mean weight reduction over 29 days.

### What side effects were reported in the BMF-650 study?

All adverse events were mild to moderate, with no severe side effects, dose changes, or study dropouts. At the highest dose level, nausea and vomiting were each reported in 12.5% of participants.

### How did Biomea Fusion stock react to the news?

Biomea Fusion Inc (NASDAQ:BMEA) stock fell 7.35% to 1.26 USD following the announcement of the Phase 1 topline clinical results.